Event Date/Time: Jun 30, 2008
Pharmacogenomics is being implemented now and is already have an impact in the clinical setting and in healthcare. Employing a pharmacogenomics strategy with marketed drugs can mitigate risk by avoiding adverse events, allowing the identification of patients most likely to benefit from a drug, and thereby improving patient compliance and safety. Tangible benefits of pharmacogenomics and resequencing technologies will be presented, and the value of this approach will be demonstrated. The regulatory perspective will be covered from the US, Europe, and Canada. In the future, a confluence of diagnostic testing, drugs and information will be required to bring new medicines to market. This meeting will show how to apply pharmacogenomics to practice.